Kasabach-Merritt syndrome is a rare but serious condition in which a fast-growing vascular tumor traps platelets and causes dangerous bleeding problems. It is seen mainly in babies and young infants, and early symptoms of Kasabach-Merritt syndrome can include a firm purple skin lump, easy bruising, swelling, or bleeding. The condition can develop quickly and may become life threatening without prompt hospital care. Not everyone will have the same experience. Treatment for Kasabach-Merritt syndrome usually aims to control the tumor and the clotting problem, often with medicines, blood product support, and sometimes a procedure or surgery.
How many people live with Kasabach-merritt syndrome?
There is no widely used direct count for Kasabach-Merritt syndrome, but Orphanet lists it in the "fewer than 1 in 1 million" range, which suggests fewer than about 8,000 people worldwide (Orphanet, 2024). Using that same rarity range, the U.S. estimate would be fewer than about 340 people, so both numbers are rough estimates rather than a direct count (Orphanet, 2024).
Overview
Kasabach-merritt syndromeSymptoms
Kasabach-Merritt syndrome often causes a rapidly enlarging, bruise-like skin lump along with easy bruising or bleeding. Babies may also seem pale, unusually sleepy, or fussy because platelets drop and anemia can develop.
Outlook and prognosis
Kasabach-Merritt syndrome can improve with fast treatment, but the outlook depends on how quickly the blood-clotting problem is controlled and whether bleeding complications develop. Many children need close follow-up while the tumor shrinks and platelet counts recover.
Causes and risk factors
Kasabach-Merritt syndrome usually develops from a rare vascular tumor, most often in infancy. It is usually not inherited and is not caused by anything a parent did. Large or fast-growing tumors raise the risk of severe bleeding and clotting problems.
Genetic influences
For Kasabach-Merritt syndrome, genetics do not seem to play a major inherited role in most cases. Current evidence suggests it usually happens sporadically, and no single genetic variation is known to explain most people living with Kasabach-Merritt syndrome.
Diagnosis
Kasabach-Merritt syndrome is diagnosed when doctors find a vascular tumor with very low platelets and abnormal clotting tests. Ultrasound or MRI helps confirm the diagnosis of Kasabach-Merritt syndrome and define the lesion.
Treatment and drugs
Kasabach-Merritt syndrome needs urgent specialist care. Treatment aims to shrink the vascular tumor and control dangerous clotting, often using medicines such as steroids or sirolimus, blood products when needed, and sometimes a procedure or surgery.
Symptoms
Kasabach-Merritt syndrome often becomes noticeable when an unusual blood-vessel growth and bleeding problems happen at the same time, most often in babies and young children. The affected area may look dark red, purple, or bruised and can get bigger fairly quickly, while low platelets make bruising and bleeding easier. Symptoms vary from person to person and can change over time.
A firm red, purple, or bruise-like patch or lump is often the first thing people notice. It may enlarge over days to weeks and can feel warm, swollen, or tight.
Easy bruising can happen even with minor bumps, and tiny red or purple dots may appear on the skin. These can be among the early symptoms of Kasabach-Merritt syndrome because the blood is not clotting as it should.
Some children bleed more than expected from the gums, nose, or the surface of the skin growth. Bleeding can also be harder to stop after blood tests, injections, or other minor procedures.
Ongoing bleeding inside the growth or elsewhere can lower the red blood cell count and lead to anemia. Many living with Kasabach-Merritt syndrome may look pale, seem unusually sleepy, or feed less well than usual.
How people usually first notice Kasabach-merritt syndrome?
Kasabach-Merritt syndrome is usually first noticed in babies or young infants when a dark red, purple, or bruise-like skin lesion starts growing quickly and becomes firm, swollen, or warm. Often, the first signs of Kasabach-Merritt syndrome are easy bruising, tiny pinpoint blood spots on the skin, bleeding, or unusual sleepiness and fussiness, which can happen because the tumor traps platelets and lowers the blood’s ability to clot. In some children the lesion is present at birth, while in others it appears soon after, and doctors often become concerned when the skin change grows fast or blood tests show a very low platelet count.
Types of Kasabach-merritt syndrome
Kasabach-Merritt syndrome does not have many formal types of its own. Instead, doctors usually describe the different types of Kasabach-Merritt syndrome by the kind of rare blood vessel tumor linked to it, because that often affects how symptoms appear and how serious they become. Symptoms don’t always look the same for everyone, but the main difference is whether the syndrome happens with kaposiform hemangioendothelioma or with tufted angioma.
Kaposiform hemangioendothelioma
This is the most common setting for Kasabach-Merritt syndrome and often causes the more severe form. Many living with this variant develop a firm, deep, bruised-looking swelling along with low platelets, easy bleeding, and fast-growing pain or swelling. The tumor can extend into deeper tissues, so symptoms may be more intense and harder to control.
Tufted angioma
This is a less common but well-recognized variant linked to Kasabach-Merritt syndrome. It may cause a red, purple, or tender patch or plaque on the skin, and the clotting problem can be milder or develop more gradually than with kaposiform hemangioendothelioma. Even so, some children with tufted angioma can still become seriously ill and need urgent treatment.
Can I slow down the onset of symptoms?
No. For Kasabach-Merritt syndrome, there is no good evidence that diet, exercise, sleep, vitamins, or other lifestyle changes can delay when symptoms begin or prevent the condition, because it is usually linked to a rare abnormal growth of blood vessels rather than everyday health habits. What can help is getting prompt medical care for a new firm skin lump, swelling, easy bruising, or bleeding, since early treatment may lower the risk of serious problems after the condition starts, even though it does not stop it from happening in the first place; while that can feel frustrating, quick expert care can still make a meaningful difference.
What genetics can tell you about symptoms
For people with Kasabach-Merritt syndrome, genetics usually does not give clear answers about which symptoms will happen, how severe they will be, or when they will start. Most cases are not known to run in families, and this condition is usually linked to a rare blood vessel tumor rather than to an inherited gene change. In practice, symptoms are more often shaped by where the tumor is, how fast it grows, and how strongly it triggers low platelets and bleeding problems than by a specific genetic finding.
Causes and risk factors
Kasabach-Merritt syndrome usually starts when a rare blood vessel growth traps platelets and uses up clotting proteins. The main biological risk is having one of these growths, most often a kaposiform hemangioendothelioma or, less often, a tufted angioma. It is seen mostly in babies and young children, and larger or deeper growths seem more likely to trigger it. Researchers are still learning how these pieces fit together, but Kasabach-Merritt syndrome is not usually caused by diet, activity, or other lifestyle habits. No clear inherited family pattern is known, and most cases seem to happen by chance.
What are the most common causes or risk factors?
Kasabach-Merritt syndrome usually happens when a rare blood vessel tumor, most often one present at birth or appearing in infancy, traps platelets, the blood cells that help stop bleeding; it is most strongly linked to kaposiform hemangioendothelioma or tufted angioma, not the common harmless infant “strawberry” birthmark. The main risk factors are being a baby or very young child and having a larger or deeper tumor, and it is usually not passed down in families, with no clear lifestyle or environmental causes known.
Environmental and biological risk factors
Kasabach-Merritt syndrome is most likely to develop in babies and young children who have a specific kind of rare vascular tumor. Doctors often group risks into internal (biological) and external (environmental). For this condition, the clearest risk factors for Kasabach-Merritt syndrome are biological, and no outside exposure has been firmly proven to trigger it.
The strongest known risk is having kaposiform hemangioendothelioma, a rare tumor made of abnormal blood vessels. This tumor is the one most often linked to Kasabach-Merritt syndrome.
A smaller number of cases happen with tufted angioma, another uncommon vascular tumor. The risk is lower than with kaposiform hemangioendothelioma, but it can still lead to the same dangerous platelet trapping.
Bigger tumors usually contain more abnormal vessels and more blood flow disturbance. That can make platelet and clotting factor use-up more likely.
Tumors that extend deep under the skin or into areas like the chest, abdomen, or retroperitoneum may carry a higher risk. They can involve a larger area before they are noticed and treated.
Genetic risk factors
For families dealing with sudden bruising, swelling, and bleeding problems, one of the first questions is whether Kasabach-Merritt syndrome runs in the family. Most of the time, it does not. Many families ask about the genetic causes of Kasabach-Merritt syndrome, but no single inherited gene has been shown to explain most cases. When gene changes are found, they are usually thought to arise only in the tumor tissue itself.
Inherited risk: No clear inherited gene cause has been confirmed for most people with Kasabach-Merritt syndrome. Parents usually do not pass the condition down, and brothers or sisters are usually not at high genetic risk.
Somatic changes: When genetic changes are involved, they are usually believed to happen after conception in the cells of the vascular tumor. That means the change is in part of the body rather than in every cell.
Related tumors: Kasabach-Merritt syndrome usually appears with a rare vascular tumor called kaposiform hemangioendothelioma, and less often with tufted angioma. The gene changes being studied are mainly in these tumor cells, not in genes inherited through a family line.
Family history: A strong family history is uncommon in Kasabach-Merritt syndrome. No clear pattern of inheritance from parent to child has been established.
Lifestyle risk factors
Kasabach-Merritt syndrome is not caused by lifestyle habits, because it develops in association with specific vascular tumors and severe platelet trapping. Still, how lifestyle affects Kasabach-Merritt syndrome can matter for bleeding risk, skin injury, recovery, and how well treatment is tolerated. The most relevant day-to-day factors are usually caregiver-driven habits rather than personal choices by the affected child.
Falls, rough play, and contact sports can increase bruising or bleeding when platelet counts are low. Choosing lower-impact activities may reduce trauma to the tumor area and lower the chance of urgent complications.
Friction, pressure, or scratching over the vascular lesion can trigger pain, skin breakdown, or bleeding. Soft clothing, careful positioning, and gentle skin care can help protect fragile tissue.
Over-the-counter drugs that affect platelets, such as aspirin or ibuprofen, can worsen bleeding risk in some patients. Families should check with the treating team before using any pain reliever, supplement, or herbal product.
Poor intake can make it harder for infants and children to recover from illness, tolerate treatment, or heal damaged skin. Good nutrition and hydration support overall resilience, especially during steroid therapy or other intensive treatment.
Risk prevention
Kasabach-Merritt syndrome usually cannot be fully prevented because it happens as a complication of certain rare blood vessel tumors, often in babies and young children. In practice, prevention means lowering the chance of serious bleeding, clotting problems, or strain on the body by spotting changes early and getting specialist care quickly. Different people need different prevention strategies—there’s no single formula. Families may first notice early symptoms of Kasabach-Merritt syndrome when a vascular birthmark or lump suddenly becomes larger, firmer, darker, or more painful, or when bruising and unusual sleepiness appear.
Quick assessment by a pediatric specialist team can lower the risk of dangerous bleeding and low platelet counts in Kasabach-Merritt syndrome. Fast treatment of the underlying vascular tumor is one of the main ways to prevent complications from getting worse.
A birthmark or soft-tissue lump that grows quickly, turns purple, feels tense, or becomes painful should be checked urgently. New bruising, tiny red spots, bleeding from the gums, or unusual paleness can signal worsening Kasabach-Merritt syndrome.
Protecting the affected area from bumps, rubbing, and pressure can help reduce bleeding into the lesion. For many living with Kasabach-Merritt syndrome, this can mean careful handling, loose clothing, and avoiding contact sports as children get older.
Blood draws, injections, surgery, and dental work may need extra planning because bleeding risk can be higher in Kasabach-Merritt syndrome. It helps to let every clinician know about the condition before any procedure.
Can you prevent Kasabach-merritt syndrome?
No, there is no known way to prevent Kasabach-Merritt syndrome. It usually happens because of a rare abnormal growth of blood vessels, and it is not thought to be caused by anything a parent did or did not do. Getting medical care quickly for a baby or child with a fast-growing lump, skin color change, unusual bruising, or bleeding may help prevent serious complications, but it does not prevent the syndrome itself.
Transmission
Kasabach-Merritt syndrome is not infectious, so it cannot be caught from another person through the air, touch, food, blood, or everyday contact. It is also not usually passed from parent to child. When families ask how Kasabach-Merritt syndrome is inherited, the answer is that it most often happens sporadically, usually in connection with a rare abnormal blood-vessel growth that develops before or soon after birth. For many living with Kasabach-Merritt syndrome, this means the condition is very unlikely to spread to others or to run in the family, although a specialist can review the details of an individual case.
When to test your genes
For Kasabach-Merritt syndrome, genetic testing is not usually part of early detection or routine care. Diagnosis is based on the vascular tumor, low platelet count, and clotting problems, not on a known inherited gene change. Gene testing may be considered only if doctors suspect a different vascular anomaly syndrome or an unusual broader condition.
Diagnosis
Kasabach-Merritt syndrome is usually suspected when a baby or young child has a fast-growing vascular tumor along with easy bruising, bleeding, or a tumor that becomes firm and swollen. It’s natural to worry when symptoms don’t have a clear explanation. The diagnosis of Kasabach-Merritt syndrome is based on the visible findings, blood tests that show a clotting problem, and imaging to define the tumor and check how far it extends.
Doctors look for a vascular tumor, often with swelling, skin color changes, pain, or rapid growth. They also ask about bruising, pinpoint bleeding spots, or bleeding that seems out of proportion to a minor injury.
Blood work usually shows a very low platelet count and signs that clotting factors are being used up too quickly. Tests may also show low fibrinogen and raised clot breakdown markers, which support the diagnosis and help track severity.
Ultrasound with Doppler is often used first to see blood flow within the tumor. MRI is commonly used to define the size, depth, and spread of the lesion and to help tell it apart from other vascular growths.
Kasabach-Merritt syndrome is most often linked to kaposiform hemangioendothelioma or tufted angioma rather than a common infantile hemangioma. Recognizing this pattern is important because the associated clotting problem can be serious and treatment differs.
How is Kasabach-merritt syndrome diagnosed?
Kasabach-Merritt syndrome is usually diagnosed when doctors find a growth made of abnormal blood vessels together with very low platelets, which are blood cells that help stop bleeding, and blood tests that show the blood is not clotting normally. They usually use a physical exam, blood tests, and imaging such as ultrasound or MRI to look closely at the growth and see how much it is affecting the body. Genetic testing is not usually part of the diagnosis, and a tissue sample, called a biopsy, is only used in some cases because it can increase the risk of bleeding.
Stages of Kasabach-merritt syndrome
Kasabach-Merritt syndrome does not have defined progression stages. This is because it is usually identified by a specific combination of problems, including a fast-growing vascular tumor and low platelets with abnormal clotting, rather than a slow step-by-step decline over time. Doctors usually start with a conversation about symptoms such as swelling, bruising, or a firm skin lump, then use blood tests and imaging scans to confirm how Kasabach-Merritt syndrome is diagnosed and monitored. In many living with Kasabach-Merritt syndrome, follow-up focuses on the size of the tumor, platelet levels, bleeding risk, and how well treatment is working.
Outlook and prognosis
The outlook for Kasabach-Merritt syndrome has improved with earlier recognition and modern treatment, but it can still be life-threatening because of severe thrombocytopenia, consumptive coagulopathy, and bleeding. Prognosis depends largely on the size and location of the underlying vascular tumor, how quickly treatment controls the coagulopathy, and whether complications such as organ compression or high-output cardiac failure occur. Infants who respond promptly to therapies such as sirolimus, corticosteroids, vincristine, or carefully selected procedures often do well, although prolonged monitoring is usually needed. Mortality has historically been significant, especially in severe or treatment-resistant cases, with older reports suggesting death rates around 10% to 30%, while outcomes in specialized centers today may be better. Even among survivors, recurrence of coagulopathy or long-term issues related to the tumor or its treatment can occur, so close follow-up is important.
Long-term effects
Kasabach-Merritt syndrome can have lasting effects even after the most dangerous phase has passed. Long-term effects vary widely, depending on how severe the blood-clotting problem was, where the tumor is located, and how well it responded to treatment. For many, this can mean ongoing changes in the skin, soft tissues, or movement, while others recover with few lasting problems.
During active Kasabach-Merritt syndrome, very low platelets and clotting problems can lead to serious bleeding. In people who recover, this risk usually improves, but some may still need long-term monitoring if the tumor remains active or grows again.
The vascular tumor linked to Kasabach-Merritt syndrome may shrink slowly rather than disappear completely. This can leave a lasting lump, fullness, or visible skin change, especially when the early symptoms of Kasabach-Merritt syndrome began in infancy.
Some people have ongoing pain, tenderness, or swelling in the affected area. If the growth involves an arm, leg, or deeper tissues, daily activities like walking, dressing, or carrying things may stay harder over time.
When the tumor affects muscles, joints, or nearby tissue, stiffness and reduced range of motion can last long term. In growing children, this may affect how a limb develops or how easily it is used.
How is it to live with Kasabach-merritt syndrome?
Living with Kasabach-Merritt syndrome can mean living with a rare vascular tumor that traps platelets, the blood cells that help stop bleeding, so daily life may revolve around watching for bruising, pain, swelling, or sudden bleeding and keeping frequent medical appointments. Many living with this condition, often infants and young children, may need hospital care, blood tests, medicines, and sometimes procedures, which can interrupt sleep, feeding, play, school, and family routines. For parents and other loved ones, the condition can bring constant vigilance and emotional strain, but careful monitoring and specialist care can make a real difference and help families regain a sense of control.
Treatment and drugs
Kasabach-Merritt syndrome needs urgent treatment because the abnormal blood vessel growth can trap platelets and clotting proteins, which raises the risk of serious bleeding and can make a baby or child look very bruised, swollen, or unwell. Treatment often aims at both problems at once: stabilizing bleeding and low platelets in the short term, while also shrinking or controlling the underlying tumor that is causing the syndrome. Doctors sometimes recommend a combination of lifestyle changes and drugs, but in Kasabach-Merritt syndrome the main treatments are usually medicines such as steroids, vincristine, or sirolimus, and some children may also need blood products, pain control, or hospital care for close monitoring. If medicine is not enough, specialists may consider procedures such as blocking the tumor’s blood supply or surgery, although the best plan depends on the child’s age, how severe the syndrome is, and where the tumor is located.
Can you cure Kasabach-merritt syndrome?
There is no simple, guaranteed cure for Kasabach-Merritt syndrome, but it can often be brought under control with treatment. Treatment focuses on shrinking the abnormal blood vessel growth causing the problem and managing the low platelet count and bleeding risk, often with medicines and sometimes blood transfusions or a procedure if needed. For many living with this condition, that means symptoms can improve and the danger can be reduced, even if care may take time and close follow-up.
Non-drug treatment
Treatment often needs to move quickly because Kasabach-Merritt syndrome can cause serious bleeding and swelling that affect day-to-day comfort and safety. Non-drug care is usually combined with medical treatment, with the main goal of controlling the tumor, protecting blood flow, and preventing complications. The best non-drug treatment for Kasabach-Merritt syndrome depends on where the tumor is, how fast it is changing, and whether vital structures are involved. Not every approach works the same way for every child, so care is usually planned by a team with experience in vascular tumors.
Surgery may be used if the tumor can be removed safely and completely. This can help stop the trapping of platelets and improve bleeding problems, but it is not possible for every tumor because some are too large or too close to important tissues.
Embolization blocks some of the blood supply feeding the tumor through a tiny tube placed in a blood vessel. It may shrink the lesion or reduce bleeding risk, and it is often used when surgery is not possible or as a step before an operation.
Carefully fitted compression wraps or garments can sometimes reduce swelling, pain, and a heavy feeling in the affected area. They are not right for every tumor, especially if the area is very tender, fragile, or at risk for poor blood flow, so specialist guidance matters.
Transfusions of platelets, red blood cells, or plasma may be needed during severe bleeding or before procedures. This supportive care does not treat the tumor itself, but it can stabilize someone while other treatment is taking effect.
Your genes may have an impact on how drugs work for you
For people living with Kasabach-Merritt syndrome, treatment response is not usually guided by inherited gene differences in the way it is for some other conditions. Right now, doctors mainly choose medicines based on how the blood vessel growth is behaving, how severe the low platelet count and bleeding risk are, and how well the person responds over time. In other words, for this condition, day-to-day care depends much more on careful monitoring than on genetic testing to predict which drug will work best.
Pharmacological treatments
Kasabach-Merritt syndrome is usually treated with medicines that shrink the underlying vascular tumor and help stop the dangerous trapping of platelets inside it. Today, sirolimus is often a main treatment, while vincristine and corticosteroids are also used, sometimes in combination. Not everyone responds to the same medication in the same way. In urgent cases, doctors may add blood-clotting support and other hospital treatments while the medicines start working.
Sirolimus is now commonly used for Kasabach-Merritt syndrome because it can slow the abnormal blood vessel growth driving the problem. It is often taken by mouth over months and needs regular blood tests to check drug levels, liver function, blood counts, and cholesterol.
Vincristine is a chemotherapy drug that has long been used when Kasabach-Merritt syndrome is severe or not improving enough with other treatment. It is usually given by vein in the hospital or clinic, and doctors watch for side effects such as constipation, jaw pain, or nerve irritation.
Steroids such as prednisone or methylprednisolone may help reduce inflammation and tumor activity, especially early in treatment. Some people improve with steroids alone, but many need another medicine added because the effect can be limited or temporary.
In some cases, medicines are combined for faster control or when the platelet count is very low. A child may receive sirolimus with a steroid, or vincristine with a steroid, as part of first-line treatment for Kasabach-Merritt syndrome.
Genetic influences
Kasabach-Merritt syndrome usually does not happen because it runs in families. It’s natural to ask whether family history plays a role, but in most cases this condition develops alongside a rare blood-vessel tumor that appears without a known inherited cause. Researchers think genetics may matter through changes that arise only in the tumor itself during early development, rather than through a gene change passed down from a parent. In a small number of these tumors, changes in genes such as GNA14 have been found, but this is not present in everyone and is not used as a routine explanation for most cases. For most families, the key point is that Kasabach-Merritt syndrome is usually considered sporadic, so the chance of it happening again in another child is generally thought to be low.
Is Kasabach-merritt syndrome genetic?
For Kasabach-Merritt syndrome, genetics do not seem to play a major inherited role in most cases. Current evidence suggests it usually happens sporadically, and no single genetic variation is known to explain most people living with Kasabach-Merritt syndrome.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a usual feature of human biology and are widespread in the general population. Most do not directly affect health and are simply part of normal human diversity. For many genes, having a variant connected to a condition points to a possible link rather than a certain diagnosis, especially when several genes and environmental factors are involved. Still, in some cases, one well-characterized variant in a particular gene is enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For families dealing with Kasabach-Merritt syndrome, the biggest issue is usually stopping the tumor from trapping platelets and causing dangerous bleeding, so treatment is guided first by how sick someone is right now. Kasabach-Merritt syndrome is not usually managed based on an inherited gene test, because doctors rely more on blood counts, imaging, and how the tumor responds to medicines such as sirolimus, steroids, or vincristine. Genetics is only one factor, and in this condition it more often affects how the body handles a drug than which drug is chosen in the first place. That means some people may need closer dose adjustments or extra monitoring if side effects show up or the medicine does not seem to work as expected. Researchers are studying genetic changes inside these rare blood-vessel tumors, but this is not yet a routine way to choose treatment for Kasabach-Merritt syndrome. If early symptoms of Kasabach-Merritt syndrome have led to several treatment changes, careful follow-up with a vascular anomalies team usually matters more than genetic testing alone.
Interactions with other conditions
People living with Kasabach-Merritt syndrome can become very sick very quickly if they also have another problem that affects bleeding or clotting. For many, this can mean that a separate illness such as a serious infection, liver disease, or an inherited bleeding disorder makes bruising, bleeding, and low blood counts harder to control. Doctors call it a “comorbidity” when two conditions occur together. Kasabach-Merritt syndrome is also more dangerous around trauma, surgery, or when someone is taking medicines that thin the blood, because the syndrome already uses up platelets and clotting proteins inside the abnormal blood vessel growth. In day-to-day care, this is why doctors often watch closely for signs of anemia, worsening swelling, or new bleeding from the gums, skin, or digestive tract. If early symptoms of Kasabach-Merritt syndrome seem to be getting worse during another illness, prompt medical review is important so treatment can be adjusted safely.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Kasabach-merritt syndrome?
The main conditions doctors often need to tell apart from Kasabach-Merritt syndrome are common infant birthmarks called hemangiomas and other unusual blood-vessel growths, because these can also cause a purple, swollen, or fast-growing lump. Problems that cause easy bruising or bleeding, such as a very low level of platelets, the blood cells that help stop bleeding, blood-clotting disorders, severe infection, or more rarely leukemia, can also look similar. Blood tests and scans help doctors tell these apart, especially when there is rapid swelling, pain, or bleeding.
History
For families, the story of Kasabach-Merritt syndrome often begins with a baby who develops a deep red, purple, or bruise-like lump that seems to enlarge quickly, while unexpected bleeding or easy bruising raises alarm. That day-to-day reality shaped how doctors first came to recognize the condition, long before modern imaging and blood testing made it easier to connect the skin finding with what was happening inside the body.
Kasabach-Merritt syndrome was first described in 1940, when doctors Haig Kasabach and Katharine Merritt reported infants with a fast-growing vascular tumor and severe problems with blood clotting. Their observations were important because they showed that some blood vessel growths were not simple birthmarks. In these babies, the tumor could trap platelets, the blood cells that help stop bleeding, and this could lead to dangerous bruising, bleeding, and low platelet counts.
As medical science evolved, doctors learned that Kasabach-Merritt syndrome is not caused by the common infant birthmark many people think of when they hear the word hemangioma. Over time, specialists recognized that it is linked to certain rare vascular tumors instead, especially in infants and young children. This change mattered because it helped explain why early symptoms of Kasabach-Merritt syndrome can be much more serious than an ordinary skin mark and why careful treatment is needed.
In recent decades, awareness has grown as better scans, pathology studies, and blood tests have improved diagnosis. Researchers also came to understand that the syndrome is a complication of the underlying tumor rather than a separate disease appearing on its own. That clearer picture has helped doctors choose more effective treatments and has improved outcomes for many living with Kasabach-Merritt syndrome.
The history of Kasabach-Merritt syndrome also includes some confusion, because older medical reports sometimes grouped different vascular conditions together under the same labels. Today, doctors are more precise about these differences. Knowing that history can be reassuring: if you read older information, it may not match current care, and modern understanding is much more accurate than it was even a few decades ago.